Polatuzumab vedotin (Polivy®) accepted for use within NHS Scotland on interim basis subject to ongoing evaluation and future reassessment

Polatuzumab intravenous infusion in combination with bendamustine and rituximab, is approved for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.


Scottish Medicines Consortium